Spots Global Cancer Trial Database for Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Official Title: A Phase 1b Study of Adaptive Androgen Deprivation Therapy for State IV Castration Sensitive Prostate Cancer

Study ID: NCT03511196

Conditions

Prostate Cancer

Stage IV Prostate Cancer

Advanced Prostate Cancer

Adenocarcinoma of the Prostate

Interventions

Adaptive Androgen Deprivation Therapy (ADT)

Abiraterone

Prednisone

Study Description

Brief Summary: Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).

Detailed Description: Investigators proposed this pilot feasibility study to use prostate specific antigen (PSA) response and testosterone level to guide the treatment with androgen deprivation therapy (ADT) \[Leuprolide, Goserelin, and Triptorelin are the most commonly used GnRH agonists for ADT\] and/or abiraterone plus prednisone. Adaptive therapy is a program of chemotherapy where the type and dosage of drug changes in an attempt to kill more of the cancer. Abiraterone acetate with prednisone is a standard of care treatment for mCRPC (metastatic castration resistant prostate cancer). It works by interrupting the male hormone (androgen) making process in the testes, adrenal glands, and tumors. This helps to prevent the growth of tumors that need these hormones to grow.